DIOSynVax to finish coronavirus vaccine trial in humans by month-end
HQ Team September 29, 2023: DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team September 29, 2023: DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of.
HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and BioNTech.